Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Atezolizumab, an Anti–Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia Study
David F. McDermott, Jeffrey A. Sosman, Mario Sznol, et al.
Journal of Clinical Oncology (2016) Vol. 34, Iss. 8, pp. 833-842
Closed Access | Times Cited: 539

Showing 1-25 of 539 citing articles:

Elements of cancer immunity and the cancer–immune set point
Daniel S. Chen, Ira Mellman
Nature (2017) Vol. 541, Iss. 7637, pp. 321-330
Closed Access | Times Cited: 4297
Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy
Suzanne L. Topalian, Janis M. Taube, Robert A. Anders, et al.
Nature reviews. Cancer (2016) Vol. 16, Iss. 5, pp. 275-287
Open Access | Times Cited: 2394
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
Arjun Vasant Balar, Matthew D. Galsky, Jonathan E. Rosenberg, et al.
The Lancet (2016) Vol. 389, Iss. 10064, pp. 67-76
Open Access | Times Cited: 1977
Development of therapeutic antibodies for the treatment of diseases
Ruei‐Min Lu, Yu‐Chyi Hwang, I-Ju Liu, et al.
Journal of Biomedical Science (2020) Vol. 27, Iss. 1
Open Access | Times Cited: 1732
PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome
Hashem O. Alsaab, Samaresh Sau, Rami M. Alzhrani, et al.
Frontiers in Pharmacology (2017) Vol. 8
Open Access | Times Cited: 1519
Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial
Thomas Powles, Ignacio Durán, Michiel S. van der Heijden, et al.
The Lancet (2017) Vol. 391, Iss. 10122, pp. 748-757
Closed Access | Times Cited: 1283
Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma
David F. McDermott, Mahrukh Huseni, Michael B. Atkins, et al.
Nature Medicine (2018) Vol. 24, Iss. 6, pp. 749-757
Open Access | Times Cited: 1095
Monitoring immune-checkpoint blockade: response evaluation and biomarker development
Mizuki Nishino, Nikhil H. Ramaiya, Hiroto Hatabu, et al.
Nature Reviews Clinical Oncology (2017) Vol. 14, Iss. 11, pp. 655-668
Open Access | Times Cited: 906
Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis
Samra Turajlic, Kevin Litchfield, Hang Xu, et al.
The Lancet Oncology (2017) Vol. 18, Iss. 8, pp. 1009-1021
Open Access | Times Cited: 821
Treatment of renal cell carcinoma: Current status and future directions
Pedro Barata, Brian I. Rini
CA A Cancer Journal for Clinicians (2017) Vol. 67, Iss. 6, pp. 507-524
Open Access | Times Cited: 748
Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials
Yucai Wang, Shouhao Zhou, Fang Yang, et al.
JAMA Oncology (2019) Vol. 5, Iss. 7, pp. 1008-1008
Open Access | Times Cited: 681
Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors
Ming Yi, Dechao Jiao, Hanxiao Xu, et al.
Molecular Cancer (2018) Vol. 17, Iss. 1
Open Access | Times Cited: 665
Incidence of Programmed Cell Death 1 Inhibitor–Related Pneumonitis in Patients With Advanced Cancer
Mizuki Nishino, Anita Giobbie‐Hurder, Hiroto Hatabu, et al.
JAMA Oncology (2016) Vol. 2, Iss. 12, pp. 1607-1607
Open Access | Times Cited: 656
Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer
Leisha A. Emens, Cristina Cruz, Joseph P. Eder, et al.
JAMA Oncology (2018) Vol. 5, Iss. 1, pp. 74-74
Open Access | Times Cited: 648
Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma
Jeffrey J. Wallin, Johanna C. Bendell, Roel Funke, et al.
Nature Communications (2016) Vol. 7, Iss. 1
Open Access | Times Cited: 626
89Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer
Frederike Bensch, Elly L. van der Veen, Marjolijn N. Lub–de Hooge, et al.
Nature Medicine (2018) Vol. 24, Iss. 12, pp. 1852-1858
Closed Access | Times Cited: 606
Cancer immunotherapy — immune checkpoint blockade and associated endocrinopathies
David J. Byun, Jedd D. Wolchok, Lynne Rosenberg, et al.
Nature Reviews Endocrinology (2017) Vol. 13, Iss. 4, pp. 195-207
Open Access | Times Cited: 601
Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study
Emmanuel S. Antonarakis, Josep M. Piulats, Marine Gross‐Goupil, et al.
Journal of Clinical Oncology (2019) Vol. 38, Iss. 5, pp. 395-405
Open Access | Times Cited: 574
The clinical role of the TME in solid cancer
Nicolás A. Giraldo, Rafael Sanchez‐Salas, J. David Peske, et al.
British Journal of Cancer (2018) Vol. 120, Iss. 1, pp. 45-53
Open Access | Times Cited: 549
Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure)
J.M. Kim, Daniel S. Chen
Annals of Oncology (2016) Vol. 27, Iss. 8, pp. 1492-1504
Open Access | Times Cited: 544
Dermatologic Reactions to Immune Checkpoint Inhibitors
V. Sibaud
American Journal of Clinical Dermatology (2017) Vol. 19, Iss. 3, pp. 345-361
Closed Access | Times Cited: 501
Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment
Ming Yi, Dechao Jiao, Shuang Qin, et al.
Molecular Cancer (2019) Vol. 18, Iss. 1
Open Access | Times Cited: 500
PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations
Yongshuai Jiang, Ming Chen, Hong Nie, et al.
Human Vaccines & Immunotherapeutics (2019) Vol. 15, Iss. 5, pp. 1111-1122
Open Access | Times Cited: 456
PD-L1 Expression in Lung Cancer
Hui Yu, Theresa A. Boyle, Caicun Zhou, et al.
Journal of Thoracic Oncology (2016) Vol. 11, Iss. 7, pp. 964-975
Open Access | Times Cited: 417
Immune-Related Adverse Events Associated with Anti-PD-1/PD-L1 Treatment for Malignancies: A Meta-Analysis
Pengfei Wang, Yang Chen, Siying Song, et al.
Frontiers in Pharmacology (2017) Vol. 8
Open Access | Times Cited: 410
Page 1 - Next Page

Scroll to top